Navigation Links
Biocon Net Profit Up by 15 Percent for Fiscal Year

Indian biotechnology major Biocon Ltd. Thursday announced a 15 percent surge in its profit at Rs.2 billion with a total income at Rs.9.9 billion in fiscal 2006-07. //

The firm's expenditure on research and development, during 2006-07, also increased by 86 percent at Rs.380 million, it said in a statement. It also announced increase in dividend from 50 to 60 percent, with Rs.3 per share, as recommended by the court.

"Our strategy of building global scale in our products and services businesses has delivered robust profits this fiscal year. This has enabled us to invest incrementally in our innovation led research programmes which will deliver attractive shareholder returns in the coming years," said Kiran Mazumdar-Shaw, chairman and managing director, Biocon Ltd.

"Today, Biocon and its subsidiaries have created a unique matrix of capabilities that has earned us a strong reputation as a preferred partner to global pharma and biotech companies," she added.

The company's subsidiary Syngene, during this period, entered into a partnership with Bristol Myers Squibb one of the world's leading pharmaceutical firms, to provide research and development (R&D) services for development of drugs.

"In the year ahead, we will continue to make significant investments to progress our innovation pipeline and leverage upon the strategic initiatives taken to enter into new business segments like oncology and nephrology whilst continuing to expand our cardio-diabetes reach globally," said Biocon's chief operating officer Arun Chandavarkar.

Source-IANS/L
'"/>




Page: 1

Related medicine news :

1. Biocon to colloborate for development of Oral peptide drugs for heart diseases.
2. Biocon To Raise Its Investment In Scotland
3. Biocon To Shift Focus On Innovation To Accelerate Growth
4. Kalam Dedicates New Cancer Drug Developed By Biocon
5. Bayer to Market Biocon Insulin in China
6. Biocon Launches Anti-Cancer Drug
7. Biocon to Launch Anti-arthritis Drug
8. Biocon Unveils Renal Therapies for Kidney Disorders
9. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
10. Premature Babies Profit From Caffeine Therapy
11. 45 Percent Of Errors In Cancer Diagnosis Harm The Patient
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: